Breaking News

KBI Biopharma Releases Inaugural FIH Manufacturing Batch at Geneva Facility

Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully.

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, announced that late in 2022, it successfully released its inaugural First In Human (FIH) manufacturing batch in compliance with current Good Manufacturing Practice (cGMP) standards in its recently expanded Geneva mammalian cell manufacturing facility. In a statement the company said that the swift execution of this important milestone demonstrates the capabilities in cell line development (CLD) and biologics manufacturing of KBI and Sele...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters